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Abstract Characterization of the biochemical steps in the
inactivation chemistry of clavulanic acid, sulbactam and
tazobactam with the carbenicillin-hydrolyzing L-lactamase
PSE-4 from Pseudomonas aeruginosa is described. Although
tazobactam showed the highest affinity to the enzyme, all three
inactivators were excellent inhibitors for this enzyme. Transient
inhibition was observed for the three inactivators before the onset
of irreversible inactivation of the enzyme. Partition ratios (kcat/
kinact) of 11, 41 and 131 were obtained with clavulanic acid,
tazobactam and sulbactam, respectively. Furthermore, these
values were found to be 14-fold, 3-fold and 80-fold lower,
respectively, than the values obtained for the clinically important
TEM-1 L-lactamase. The kinetic findings were put in perspective
by determining the computational models for the pre-acylation
complexes and the immediate acyl-enzyme intermediates for all
three inactivators. A discussion of the pertinent structural factors
is presented, with PSE-4 showing subtle differences in interac-
tions with the three inhibitors compared to the TEM-1 enzyme.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Infections caused by Pseudomonas aeruginosa are increas-
ingly becoming a serious problem due to multiple-drug resis-
tant strains of these bacteria [1]. In the mid 1980s, infections
caused by most of the P. aeruginosa strains were manageable
by antibiotics. However, by the early 1990s, 25% of these
strains developed various resistant mechanisms [2]. The treat-
ment strategies for the infections of P. aeruginosa are a cause
of concern, especially in immunocompromised and cystic ¢-
brosis patients, and in hospitals [3,2]. As in other bacteria,
P. aeruginosa expresses L-lactamases as part of its resistance
arsenal [4]. Production of L-lactamase by bacteria is the major
mechanism of resistance to L-lactam antibiotics. These en-
zymes hydrolyze the lactam ring of the L-lactam drugs, neu-
tralizing their antibiotic activity [5].
P. aeruginosa produces various L-lactamases including so-
called Pseudomonas-speci¢c L-lactamases, or PSE (for ‘Pseu-
domonas-speci¢c enzyme’), in addition to other plasmid and
chromosome-mediated enzymes [3,6]. PSE-4 is a class A plas-
mid-mediated L-lactamase and belongs to the family of ‘car-
benicillinases’ which hydrolyze carbenicillin as e⁄ciently or
better than aminopenicillins [7^9]. PSE-type L-lactamases are
also known to be part of transposable elements and trans-
ferred to other bacterial species altering their resistance pro-
¢les [10^13]. The PSE-4 enzyme is the most frequent L-lac-
tamase found in carbenicillin resistant clinical strains of
P. aeruginosa [7].
L-Lactam antibiotics are the most commonly used group of
antibiotics in treatment of infections. This extensive use of
L-lactam antibiotics creates a high selective pressure for the
bacterial ecosystems, where new variants of common L-lacta-
mases have emerged. These variants can hydrolyze L-lactam
molecules which traditionally resisted the hydrolytic action of
L-lactamases, or resist inactivation by the clinically used in-
hibitors, such as clavulanic acid (1), sulbactam (2) and tazo-
bactam (3) [14^20]. A total of 67 variants of the TEM-1
L-lactamase, which is the most common enzyme among the
class A L-lactamases, have been identi¢ed to date from clinical
strains ([8,21,22], http://www.lahey.hitchcock.org/pages/lhc/
studies/webt.htm). The prevalence of these variants and the
continuous discovery of newer L-lactamases represent a seri-
ous threat to the treatment of bacterial infections. In most
cases, the novel catalytic behavior of these mutants is due
to mutations that alter the enzyme such that the substrate
speci¢city is often broadened [23,24].
The understanding of the inactivation chemistry of L-lac-
tamase inhibitors is the ¢rst step for the rational design of
future generations of potent inhibitors [25,26]. The TEM-1
and PSE-4 L-lactamases are both from Gram-negative bacte-
ria and the enzymes share some similarity in their sequences
[7]. However, in light of the fact that the responses of Esche-
richia coli and P. aeruginosa to antibiotic treatment are quite
distinct from one another, it is critical that the inhibition
behavior of the L-lactamases from these organisms with the
clinically used inhibitors are compared and contrasted to each
other. We have undertaken such an e¡ort and a structure-
based study of the inactivation process of PSE-4 by inhibitors
clavulanic acid, sulbactam and tazobactam. A discussion is
presented on the similarities and subtle di¡erences between
the inhibition processes for PSE-4 and TEM-1.
2. Materials and methods
Ticarcillin and clavulanic acid were kindly provided by Smith Kline
Beecham Pharmaceuticals. Sulbactam and tazobactam were provided
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by P¢zer and SynPhar Laboratories, respectively. All other antibiotics
were purchased from Sigma.
2.1. Antibiotic susceptibility testing
Minimal inhibitory concentrations (MICs) were determined by the
broth microdilution method. An inoculum of 105 colony-forming
units of E. coli DH5K (pMON711) expressing PSE-4 or the plasmid-
less strain was prepared by dilutions and inoculated into microtiter
wells containing 100 Wl of a binary dilution of an antibiotic in the
Mueller^Hinton broth. The range of concentrations tested varied
from 10 to 20 000 Wg/ml for carbenicillin, ampicillin and piperacillin.
The concentrations of the inhibitors clavulanic acid, sulbactam and
tazobactam were maintained at 8 Wg/ml and plates were incubated for
24 h at 37‡C. The lowest concentration which inhibited bacterial
growth (monitored by visual inspection) was recorded as the MIC.
2.2. Puri¢cation of L-lactamases
L-Lactamases were prepared from 6 l of Terri¢c Broth (Difco Lab-
oratories, Detroit, MI, USA) supplemented with 50 Wg/ml of kana-
mycin and 50 Wg/ml of ampicillin and inoculated with E. coli JM101
expressing PSE-4. The L-lactamases were isolated with a standard
osmotic shock procedure and puri¢ed to homogeneity (99.9%) accord-
ing to a previously described procedure [27]. Protein concentrations
were determined with a Bradford protein assay using Bio-Rad con-
centrated reagent for protein assays and calculated with a linear re-
gression analysis.
2.3. Kinetic analysis
Kinetic measurements were determined with a Hewlett-Packard
8453 diode-array instrument. The data were analyzed with the Hew-
let-Packard 845X UV-VIS and Microsoft Excel software. All enzy-
matic reactions were performed in 50 mM sodium phosphate bu¡er at
pH 7.0. In standard assays, hydrolysis of benzylpenicillin was moni-
tored at 240 nm (A= 540 M31 cm31) at room temperature. All deter-
minations were done in duplicate.
The partition ratio was determined using the titration method
[4,28]. Various molar ratios of inhibitor to enzyme mixtures (I/E)
ranging from 0.5 to 100, 50 to 150 and 0.05 to 10 for clavulanic
acid, sulbactam and tazobactam, respectively, were prepared and in-
cubated at 4‡C for approximately 20 h. The residual enzyme activity
was measured by adding 20 Wl of each mixture to 980 Wl of a bu¡ered
solution of 2 mM benzylpenicillin at pH 7.0. The rates of hydrolysis
of benzylpenicillin were measured after complete recovery from tran-
sient inhibition since a gradual increase in the rate of hydrolysis was
time-dependent, particularly with high ratios of I/E. An inhibitor-free
mixture was also included in the assays as a negative control to esti-
mate non-speci¢c inactivation.
The ¢rst-order rate constants for inactivation (kinact) were deter-
mined by the protocol described by Imtiaz et al. [28]. Increasing con-
centrations of inhibitors, 20^1000 nM, 200^4000 nM and 20^400 nM
for clavulanic acid, sulbactam and tazobactam, respectively, were
added to 200 nM of enzyme in 50 mM sodium phosphate bu¡er at
pH 7.0 and incubated on ice. At regular time intervals of 90 s, for a
total of ¢ve measurements, a 20 Wl aliquot of enzyme^inhibitor mix-
ture was removed and added to 980 Wl of 2 mM of benzylpenicillin in
sodium phosphate bu¡er (pH 7.0) to measure the remaining activity.
The value for kinact was determined using a double-reciprocal plot of
the observed rates of inactivation (kobs) versus inhibitor concentra-
tions [28].
The dissociation constants (Ki) for the three inhibitors were deter-
mined using a Dixon plot. Two concentrations of benzylpenicillin
(300 and 500 nM) were used with various concentrations of inhibitors,
0.5^20 nM, 0.5^15 nM and 0.1^0.75 nM for clavulanic acid, sulbac-
tam and tazobactam, respectively. The enzyme was added to the sub-
strate^inhibitor mixture giving a ¢nal concentration of 5 nM in a total
reaction volume of 1 ml. The activity was measured immediately and
calculated from the highest linear rate of substrate hydrolysis.
2.4. Molecular modeling of the pre-acylation complexes and the
acyl-enzyme intermediates
The amino acid sequence of P. aeruginosa L-lactamase (PSE-4) was
obtained from the Swiss-Prot data bank (accession number P16897).
Similarity search was performed to extract closely related sequences in
the Brookhaven protein data bank, using the BLASTP program [29].
The TEM-1 L-lactamase was the closest enzyme based on this crite-
rion, and was used as the template to build the three-dimensional
model for the PSE-4 L-lactamase. The COMPOSER program (Tripos
Associates, St. Louis, MO, USA) was used to align the sequences and
construct the three-dimensional model of PSE-4 L-lactamase. This
program can successfully be used to predict the three-dimensional
structure of a protein sequence using the three-dimensional structure
of another if the two sequences show at least 30% homology [30].
PSE-4 L-lactamase showed 40% identity with the TEM-1 L-lactamase.
The structure of PSE-4 L-lactamase from the residue Phe-22 through
Tyr-283 (numbering according to the Swiss-Prot sequence; corre-
sponds to Phe-27 through Tyr-289 according to Ambler nomenclature
[31]) was predicted using the structurally conserved regions based on
the alignment of these sequences. The numbering of the residues used
henceforth is in correspondence with that of TEM-1, according to
[31]. The signi¢cant di¡erence between the active site of PSE-4 and
TEM-1 L-lactamase is that Lys-234 in TEM-1 corresponds with Arg-
234 in PSE-4 L-lactamase. All other residues, viz. Ser-70, Lys-73, Tyr-
105, Ser-130, Asn-132, Glu-166, Asn-170, Ser-235, Arg-244 and Asn-
276 [37], in PSE-4 L-lactamase correspond to similar spatial locations
as those seen in TEM-1 L-lactamase, adding con¢dence to the reli-
ability of the predicted three-dimensional structure of PSE-4.
The predicted model of PSE-4 L-lactamase was carefully analyzed
for any bad orientations of the side chains and the structure was
relaxed using the Sibyl molecular modeling program for 200 itera-
tions. Subsequently, the crystallographic water molecules from the
X-ray structure of TEM-1 L-lactamase (1btl) were added to the
PSE-4 model (total of 196 waters were retained out of 199) and the
model was energy-minimized using the AMBER program for 20 000
iterations using all-atom force ¢eld. The CK carbons of the energy-
minimized structure of PSE-4 L-lactamase showed an rms deviation of
1.2 Aî when compared with those of the X-ray crystal structure of
TEM-1 L-lactamase (1btl). Inhibitor molecules (clavulanic acid, sul-
bactam and tazobactam) were either obtained from the Cambridge
Structural Database or constructed in SYBYL and the ESP charges
were calculated using the MNDO method in the MOPAC program.
The enzyme^substrate pre-acylation complexes and the acyl-enzyme
complexes (total of six) were constructed and energy-minimized to
obtain the ¢nal models.
2.5. Molecular dynamics
To get insight on the movements of the putative linear species of
inhibitor in the active site and to verify the proximity of active site
nucleophile to iminium carbon of inhibitors, we used molecular dy-
namics simulations. The minimized complexes were heated to 310 K
over 16 ps and equilibrated for 40 ps at 310 K. The simulation was
carried for 56 ps using a time step of 1 ft. A total of eight conforma-
tions were sampled every 5 ps for each linearized inhibitor complex.
The 24 conformations were then minimized to relieve the energy con-
straint until the energy gradient reached a value smaller or equal to
0.001 kcal/mol/Aî .
All the computational work was performed with Sibyl package
version 6.3 on a Silicon Graphics Octane workstation. Distances be-
tween relevant active site residues, water molecules and functional
groups of inactivators were determined with the functions of the view-
er module of Insight II package version 95.0 (MSI, San Diego, CA,
USA) on a Silicon Graphics Elan R4000 workstation. Generation of
the putative inactivating species and dynamic simulations of the lin-
earized inhibitors were performed with the MOE package version
1998 (Chemical Computing Group, Montreal, Que., Canada) on a
Silicon Graphics workstation. The linear species for each inhibitor
were generated by opening the bond between atom C5 and the oxy-
gen/sulfur using MOE and based upon previous structures [28,32,33].
Prior to molecular dynamics, each linear inhibitor was energy-mini-
mized.
3. Results and discussion
3.1. Susceptibility testing
Expression of the L-lactamase PSE-4 in E. coli DH5K con-
ferred high level resistance towards ampicillin, piperacillin and
ticarcillin, as shown by the MIC values depicted in Table 1.
The use of clavulanic acid in combination with ampicillin or
ticarcillin decreased the MICs by 400-fold and 80-fold, respec-
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tively, thus restoring susceptibility to ampicillin (MIC of
12.5 Wg/ml); while resistance to ticarcillin was still maintained
(MIC of 250 Wg/ml). This di¡erence is essentially due to the
higher level of catalytic activity of PSE-4 towards ticarcillin.
The combination of ampicillin with sulbactam or tazobactam
failed to restore susceptibility to ampicillin for E. coli express-
ing PSE-4. Overall, the most potent inactivators used in com-
bination with ampicillin were in order of increasing e⁄cacy
sulbactam, tazobactam and clavulanic acid. These results are
consistent with the kinetics of inactivation with the puri¢ed
L-lactamase (described below), where the kinetics followed a
similar pattern. Finally, the protective e¡ect of tazobactam
for piperacillin was obvious as the MIC of piperacillin de-
creased by 256-fold, restoring complete susceptibility to piper-
acillin.
3.2. Molecular modeling
The pre-acylation complexes and the immediate acyl-en-
zyme intermediates for clavulanic acid, sulbactam and tazo-
bactam in the active site of PSE-4 L-lactamase (a total of six
complexes) were generated according to the procedure pub-
lished earlier [34], and the complexes were energy-minimized.
Schematic diagrams of the pre-acylation complexes and the
acyl-enzyme intermediates are depicted in Fig. 1A,B. Table 2
gives the distances among the relevant functional groups of
inactivators and the enzyme. Fig. 2 depicts these complexes in
stereo projections.
3.3. The pre-acylation complex
In all the three computed pre-acylation complexes (Fig. 2A^
C), the carbonyl moiety of the lactam ring of all three inhib-
itors formed hydrogen bonds with the backbone nitrogen of
Ser-70 and Ala-237 in the oxyanion hole (Table 2). A hydro-
gen bond network is present between the C3 carboxylate of
the inhibitors and the residues Arg-234, Ser-235, Arg-244 and
Ser-139 (located in the L-3 and L-4 strands, and loop between
helices K-H4 and K-H5, respectively). It is noteworthy that
PSE-4 has an Arg-234 (like other enzymes of group 2c of
Bush’s classi¢cation, [10]) instead of a Lys residue which is
present in most class A L-lactamases [8]. The guanidinium
group of Arg-234 is expected to participate actively in sub-
strate recognition in the catalytic activity of PSE-4 [7]. The
correct positioning of the L-lactam molecule is crucial to per-
mit the nucleophilic attack of the susceptible carbonyl atom of
the lactam ring by Ser-70. On the basis of the calculated dis-
tances, the C3 carboxylate of the inhibitors and Arg-244 in-
teract via a hydrogen bond in the pre-acylation complex of all
three inhibitors in the PSE-4 active site. Furthermore, a weak
hydrogen bond between Ser-130 and the nitrogen of the lac-
Scheme 1.
Table 1
MICs (Wg/ml) of E. coli DH5K expressing the wild-type PSE-4
L-Lactams in combination with L-lactamase inactivators MIC (Wg/ml)
DH5K alone DH5K with wild-type PSE-4
ampicillin 6 2.4 5 000
piperacillin 1.0 1 000
ticarcillin 6 10 20 000
ampicillin+clavulanic acid 8a 3.1 12.5
ampicillin+sulbactam 8b 1.6 400
ampicillin+tazobactam 8c 0.78 100
ticarcillin+clavulanic acid 8d 2.0 250
piperacillin+tazobactam 8e 1.0 4.0
a, b, c, ampicillin+8 Wg/ml of clavulanic acid or sulbactam or tazobactam; d, ticarcillin+8 Wg/ml of clavulanic acid; e, piperacillin+8 Wg/ml of
tazobactam.
Fig. 1. A schematic drawing of the active site of the PSE-4 enzyme
illustrating the distances among important amino acids and func-
tional groups of the inactivator(s) for the pre-acylation complex and
the immediate acyl-enzyme species.
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Fig. 2. Computational models of the pre-acylation complex and the immediate acyl-enzyme intermediates of the PSE-4 L-lactamase and the in-
hibitors, clavulanic acid (A and D, respectively), sulbactam (B and E, respectively) and tazobactam (C and F, respectively). The active site is
shown for the regions within the vicinity of the inhibitor complex of PSE-4 L-lactamase. The inhibitor is shown in bold and the protein resi-
dues are in gray.
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Fig. 2 (continued).
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tam ring was observed in the pre-acylation intermediates of
sulbactam and tazobactam.
3.4. The acyl-enzyme intermediates of the three inhibitors
The immediate acyl-enzyme species of clavulanic acid, sul-
bactam and tazobactam in the active site of PSE-4 L-lactam-
ase revealed interesting features (Fig. 2D^F). This species for
clavulanate is depicted by structure 4 in Scheme 1. The ester
carbonyl moiety was retained in the oxyanion hole through
hydrogen bonds to the backbone nitrogens of Ser-70 and Ala-
237. Whereas the ring opening from the immediate acyl-en-
zyme species to the inactivating linear species for sulbactam
and tazobactam is a relatively simple event, this step is more
complicated for clavulanic acid. Clavulanic acid would bene¢t
from a protonation process in the ring opening process (such
as 5, 6, 7). This process is made possible by the arrangement
of functionalities in the active sites of class A L-lactamases.
The hydrogen bonds between the C3 carboxylate of the in-
hibitors with Ser-130, Arg-234, Ser-235 and Arg-244 were seen
in all three acyl-enzyme species. Interestingly, Wat-3452 (cor-
responding spatially to Wat-673 in Imtiaz et al. [28]) forms a
bridge between the carboxylate of all three inhibitors used in
this study and the side chain of Arg-244. This water molecule
was implicated to play a function as a source of a critical
proton in the inactivation chemistry of clavulanate with the
TEM-1 enzyme (Scheme 1; 5, 6 [24]). Formation of the linear
inactivation species 7 (6, 7) would be triggered by protonation
of the C8 carbon of the carbanion species 5 and the likely
source of this proton was attributed to be Wat-673 [24]. It was
proposed that the clavulanate carboxylate might function as a
general base, facilitating the transfer of a proton from Wat-
673 to the C8 of the carbanion species [24]. Due to the similar
interactions observed in the models of TEM-1 and PSE-4
L-lactamases, the inactivation chemistries are probably similar
in both cases.
Species 5 would trap an active site nucleophilic residue to
give species 8, which accounts for the irreversible inhibition of
the enzyme. This nucleophilic amino acid was shown to be
Ser-130 for the case of inactivation of the TEM-1 enzyme
[32,35]. The linear species for each inhibitor were generated
by opening the bond between atom C5 and the oxygen/sulfur
using MOE and based upon previous structures [28,32,33].
The three linear species were generated, energies were mini-
mized for each individually. Simulations were then performed
followed by selection of structures in the time course of sim-
ulation and minimization of energies for each individually.
Molecular dynamic simulations were carried out to deter-
mine which of the active site nucleophiles of PSE-4 L-lactam-
ase were implicated in the capture of the iminium carbon of
the three inhibitors. The mean distances of active site nucleo-
philes to C5 of inhibitors are depicted in Table 3. Based upon
the inter-atomic distances measured from the eight minimized
conformations sampled during the dynamic simulation, we
noted that Lys-73 or Arg-244 could be probable candidates
responsible for the capture of the iminium species of clavu-
lanic acid; however, Arg-244 cannot function as a nucleo-
phile. Also, the participation Ser-130 in that reaction could
be ruled out with an average distance of 6.1 Aî . Interestingly,
two di¡erent amino acids were identi¢ed to participate in the
irreversible inactivation of PSE-4 by the penicillin sulfones. In
the case of sulbactam, Lys-73 at an average distance of 4.8 Aî
is the most probable candidate, while Ser-130 at 4.5 Aî would
perform the same function with tazobactam. The inter-
actions of the triazole moiety of the latter clearly a¡ect the
inactivation chemistry of tazobactam. Hence, the conforma-
tion of the PSE-4 active site contains subtle di¡erences with
Table 3
Average distances in Aî between potential active site nucleophiles of PSE-4 and C5 of the linearized inhibitor complex
Lys-73 NO Ser-130 OQ Arg-244 N1 Arg-244 N2
Clavulanic acid 5.7a 6.1 7.5 6.2
Sulbactam 4.8 5.4 10.6 8.9
Tazobactam 7.2 4.5 6.7 5.5
aValues in bold indicate potential interactions between the concerned nucleophile and C5 of the inhibitor.
Table 2
Calculated distances between non-hydrogen atoms in the minimized complexes
Distances in Fig. 1 Groups involved Pre-acylation complex (Aî ) Acyl-enzyme complex (Aî )
clv slb taz clv slb taz
A Ser-70 N to lactam CO 3.0a 3.2 3.0 2.7 2.7 2.7
B Ala-237 N to lactam CO 2.8 2.8 2.7 2.9 2.77 2.77
C Ser-130 OQ to lactam N 3.3 3.1 3.3 4.6 3.5 4.0
DP Ser-130 OQ to O01 4.6 4.8 4.8 2.6 4.8 2.6
D Ser-130 OQ to O03 2.6 2.7 2.7 4.0 2.7 4.4
EP Arg-234 N1 to O01 4.6 4.6 4.6 2.7 6.3 2.8
E Arg-234 N1 to O03 2.7 2.8 2.9 4.6 4.6 2.6
F Ser-235 OQ to O01 2.6 2.7 2.7 3.0 2.8 3.1
FP Ser-235 OQ to O03 3.1 4.3 4.3 2.6 2.8 2.6
G Arg-244 O2 to O01 2.7 2.8 2.8 4.5 2.6 4.8
GP Arg-244 N2 to O03 4.7 4.9 4.9 2.7 4.8 2.6
H Arg-244 N1 to W3452 2.7 2.7 2.7 2.7 2.7 2.7
I W3452 to O01 2.7 2.7 2.7 4.6 2.7 4.3
IP W3452 to O03 4.4 4.4 4.4 2.6 4.1 2.9
clv, clavulanate; slb, sulbactam; taz, tazobactam.
aValues in bold indicate potential hydrogen bonding between the corresponding groups. Average distance of a hydrogen bond: 2.7^3.1 Aî .
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TEM-1 which can only be con¢rmed by crystallography stud-
ies.
3.5. Kinetic analyses
Kinetic evaluation of the three clinically used inhibitors,
clavulanic acid, sulbactam and tazobactam, was performed
with PSE-4 (Table 4). The binding a⁄nity of the inhibitors
in the active site of PSE-4 was investigated by determining the
dissociation constant Ki. Clavulanic acid and sulbactam
showed similar Ki (4 and 12 WM, respectively). It is notewor-
thy that tazobactam showed a considerably higher a⁄nity for
this enzyme (Ki of 150 nM); 80-fold higher a⁄nity than for
sulbactam. The triazole moiety of tazobactam is the only
structural di¡erence. Examination of the pre-acylation model
of tazobactam in the PSE-4 active site indicated the existence
of hydrogen bonds between the N3 and N4 nitrogen atoms of
the triazole ring with Tyr-105. The interactions of the enzyme
with the triazole of tazobactam are clearly important in en-
hancing a⁄nity.
Transient inhibition was observed with each inhibitor, as
seen previously with other L-lactamases, especially at high
inhibitor to enzyme ratios because a gradual increase in the
rate of hydrolysis was observed during the course of substrate
turnover. Clavulanic acid, sulbactam and tazobactam were
individually turned over 11, 131 and 41 times, respectively,
before each inactivation event of the enzyme (Table 4). Con-
sistent with previous kinetic studies on other class A enzymes,
clavulanic acid appeared to be the most potent inhibitor
against PSE-4 both in terms of exhibiting the best (lowest)
partition ratio (i.e. kcat/kinact) as well as the most rapid ¢rst-
order rate constant for inactivation (i.e. kinact). The most strik-
ing result is the partition ratio of sulbactam measured with
PSE-4 (kcat/kinact = 131) which is 76-fold lower compared to
the value measured with TEM-1 (kcat/kinact = 10 000); [28,33].
Another interesting observation is that the three inactivators
are turned over with comparable rate constants (i.e. kcat). The
partition ratios of clavulanic acid and tazobactam were 14-
fold and 3-fold lower than the values calculated with TEM-1
and TEM-2 enzymes, respectively [33,36]. The PSE-4 enzyme
appears to be exquisitely sensitive to the three clinical inhib-
itors of L-lactamases, generally more so than other common
class A enzymes such as the TEM variants which have been
the subject of similar analysis. This fact bodes well for inter-
vention in the clinic, since Pseudomonal infections are gener-
ally hard to treat and would support the tazobactam^piper-
acillin combination recommended. An in-depth analysis of the
PSE-4 active site and its interaction with inhibitors should
assist in de¢ning the mechanism of inhibition for carbenicil-
lin-hydrolyzing L-lactamases [3]. Optimization by energy min-
imization of stable complexes occurring along the pathway of
hydrolysis of benzylpenicillin and cephalosporin C explained
the mechanism of acyl transfer by the class A L-lactamase of
Streptomyces albus G and the di¡erences found in the Kcat
values with these substrates [38]. The data reported here ex-
tend modeling studies on the hydrolytic mechanism of class A
L-lactamases, and those done with the three clinically useful
inhibitors [20,27,28,33,39].
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